Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Dermatitis, Atopic: full-pipeline trial registry
6 of 30 indexed Dermatitis, Atopic trials are currently recruiting.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 6 currently recruiting · #519 of 28,707 conditions by registered trial count
Dermatitis, Atopic: 30 US clinical trials tracked, 6 recruiting.
Dermatitis, Atopic is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi, running 9 of these trials.
Enrollment posture brief
Registry condition dermatitis-atopic
OPEN 6 | RECR 20% | LATE 10 | EARLY 12 | RANK #519 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Dermatitis, Atopic lists 6 open slots (20% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Dermatitis, Atopic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Dermatitis, Atopic is recruiting below its size-band peers.
6 of 30 indexed trials (20%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Dermatitis, Atopic research.
Sanofi accounts for 9 of 30 trials (30%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Dermatitis, Atopic enrolment sits around 226 participants.
Median target enrolment is 226 among the 30 trials that report a genuine target (sentinel values excluded). 8 of those (26.7%) plan for fewer than 100 participants.
-
Dermatitis, Atopic research is mostly interventional.
25 interventional and 5 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Sanofi
NCT05769777
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Sanofi
NCT06241118
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
Janssen Research & Development
NCT07230860
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
Pfizer
NCT06899204
Effects of Treatments on Atopic Dermatitis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT01631617
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
Nexgen Dermatologics
NCT06488742
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
Sanofi
NCT03687359
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi
NCT06407934
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
Regeneron Pharmaceuticals
NCT03428646
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
Sanofi
NCT03849716
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
Janssen Research & Development
NCT06881251
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Sanofi
NCT06790121
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
Sanofi
NCT05983068
Histamine Pharmacogenetics in Children With Atopic Dermatitis
Virginia Commonwealth University
NCT00277433
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
NCT02277769
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Regeneron Pharmaceuticals
NCT02277743
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Sanofi
NCT06224348
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
Regeneron Pharmaceuticals
NCT03345914
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Regeneron Pharmaceuticals
NCT03054428
Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook
Boston Children's Hospital
NCT03722706
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis
Astellas Pharma
NCT00666159
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
Sanofi
NCT06015308
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
Regeneron Pharmaceuticals
NCT03346434
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
Formation Bio
NCT05870865
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
Pfizer
NCT01602341
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
Merck Sharp & Dohme
NCT05450198
Topical Steroid Formulation and Wet Wraps
Seton Healthcare Family
NCT02680301
A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area
Johnson & Johnson Consumer Inc. (J&JCI)
NCT05226143
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
Pfizer
NCT04135560
Study to Evaluate ASN008 Topical Gel (TG)
Asana BioSciences
NCT03798561
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 9 |
| Phase 3 | 7 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Dermatitis, Atopic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Dermatitis, Atopic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Dermatitis, Atopic page
30 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Dermatitis, Atopic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sanofi sponsors the most Dermatitis, Atopic trials on record, review their full trial history before evaluating a specific study. See Sanofi's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dermatitis, Atopic condition card totals 30 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.